TABLE OF CONTENT: 1. Introduction 1.1. ResearchScope 1.2. MarketSegmentation 1.3. ResearchMethodology 1.4. Definitionsand Assumptions 2. ExecutiveSummary 3. MarketDynamics 3.1. MarketDrivers 3.2. MarketRestraints 3.3. MarketOpportunities 4. KeyInsights 4.1. PipelineAnalysis 4.2. Overviewof Regulatory Scenario by Key Regions 4.3. KeyIndustry Developments 4.4. Numberof Primary Immunodeficiency (PI) Patients by Key Countries 4.5. Overviewof Reimbursement Scenario 5. GlobalImmunoglobulins Market Analysis, Insights and Forecast, 2015-2026 5.1. Key Findings / Summary 5.2. MarketAnalysis, Insights and Forecast – By Route of Administration 5.2.1. Intravenous(IV) 5.2.2. Subcutaneous(SC) 5.3. MarketAnalysis, Insights and Forecast – By Indication 5.3.1. PrimaryImmunodeficiency 5.3.2. ChronicInflammatory Demyelinating Polyneuropathy (CIDP) 5.3.3. Guillain-BarréSyndrome (GBS) 5.3.4. ImmuneThrombocytopenic Purpura (ITP) 5.3.5. MultifocalMotor Neuropathy (MMN) 5.3.6. Others 5.4. MarketAnalysis, Insights and Forecast – By Form 5.4.1. Liquid 5.4.2. Lyophilized 5.5. MarketAnalysis, Insights and Forecast – By End User 5.5.1. Hospitals 5.5.2. Clinics 5.5.3. Homecare 5.6. MarketAnalysis, Insights and Forecast – By Region 5.6.1. NorthAmerica 5.6.2. Europe 5.6.3. AsiaPacific 5.6.4. LatinAmerica 5.6.5. MiddleEast & Africa 6. NorthAmerica Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026 6.1. KeyFindings / Summary 6.2. MarketAnalysis – By Route of Administration 6.2.1. Intravenous(IV) 6.2.2. Subcutaneous(SC) 6.3. MarketAnalysis – By Indication 6.3.1. PrimaryImmunodeficiency 6.3.2. ChronicInflammatory Demyelinating Polyneuropathy (CIDP) 6.3.3. Guillain-BarréSyndrome (GBS) 6.3.4. ImmuneThrombocytopenic Purpura (ITP) 6.3.5. MultifocalMotor Neuropathy (MMN) 6.3.6. Others 6.4. MarketAnalysis – By Form 6.4.1. Liquid 6.4.2. Lyophilized 6.5. MarketAnalysis – By End User 6.5.1. Hospitals 6.5.2. Clinics 6.5.3. Homecare 6.6. MarketAnalysis – By Country 6.6.1. U.S. 6.6.2. Canada 7. EuropeImmunoglobulins Market Analysis, Insights and Forecast, 2015-2026 7.1. KeyFindings / Summary 7.2. MarketAnalysis – By Route of Administration 7.2.1. Intravenous(IV) 7.2.2. Subcutaneous(SC) 7.3. MarketAnalysis – By Indication 7.3.1. PrimaryImmunodeficiency 7.3.2. ChronicInflammatory Demyelinating Polyneuropathy (CIDP) 7.3.3. Guillain-BarréSyndrome (GBS) 7.3.4. ImmuneThrombocytopenic Purpura (ITP) 7.3.5. MultifocalMotor Neuropathy (MMN) 7.3.6. Others 7.4. MarketAnalysis – By Form 7.4.1. Liquid 7.4.2. Lyophilized 7.5. MarketAnalysis – By End User 7.5.1. Hospitals 7.5.2. Clinics 7.5.3. Homecare 7.6. MarketAnalysis – By Country/ Sub-Region 7.6.1. U.K. 7.6.2. Germany 7.6.3. France 7.6.4. Spain 7.6.5. Italy 7.6.6. Scandinavia 7.6.7. Restof Europe 8. AsiaPacific Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026 8.1. KeyFindings / Summary 8.2. MarketAnalysis – By Route of Administration 8.2.1. Intravenous(IV) 8.2.2. Subcutaneous(SC) 8.3. MarketAnalysis – By Indication 8.3.1. PrimaryImmunodeficiency 8.3.2. ChronicInflammatory Demyelinating Polyneuropathy (CIDP) 8.3.3. Guillain-BarréSyndrome (GBS) 8.3.4. ImmuneThrombocytopenic Purpura (ITP) 8.3.5. MultifocalMotor Neuropathy (MMN) 8.3.6. Others 8.4. MarketAnalysis – By Form 8.4.1. Liquid 8.4.2. Lyophilized 8.5. MarketAnalysis – By End User 8.5.1. Hospitals 8.5.2. Clinics 8.5.3. Homecare 8.6. MarketAnalysis – By Country/ Sub-Region 8.6.1. Japan 8.6.2. China 8.6.3. India 8.6.4. Australia 8.6.5. SoutheastAsia 8.6.6. Restof Asia Pacific 9. LatinAmerica Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026 9.1. KeyFindings / Summary 9.2. MarketAnalysis – By Route of Administration 9.2.1. Intravenous(IV) 9.2.2. Subcutaneous(SC) 9.3. MarketAnalysis – By Indication 9.3.1. PrimaryImmunodeficiency 9.3.2. ChronicInflammatory Demyelinating Polyneuropathy (CIDP) 9.3.3. Guillain-BarréSyndrome (GBS) 9.3.4. ImmuneThrombocytopenic Purpura (ITP) 9.3.5. MultifocalMotor Neuropathy (MMN) 9.3.6. Others 9.4. MarketAnalysis – By Form 9.4.1. Liquid 9.4.2. Lyophilized 9.5. MarketAnalysis – By End User 9.5.1. Hospitals 9.5.2. Clinics 9.5.3. Homecare 9.6. MarketAnalysis – By Country/ Sub-Region 9.6.1. Brazil 9.6.2. Mexico 9.6.3. Restof Latin America 10. MiddleEast & Africa Immunoglobulins Market Analysis, Insights and Forecast,2015-2026 10.1. Key Findings / Summary 10.2. Market Analysis – By Route of Administration 10.2.1. Intravenous (IV) 10.2.2. Subcutaneous (SC) 10.3. MarketAnalysis – By Indication 10.3.1. Primary Immunodeficiency 10.3.2. Chronic Inflammatory Demyelinating Polyneuropathy(CIDP) 10.3.3. Guillain-Barré Syndrome (GBS) 10.3.4. Immune Thrombocytopenic Purpura (ITP) 10.3.5. Multifocal Motor Neuropathy (MMN) 10.3.6. Others 10.4. MarketAnalysis – By Form 10.4.1. Liquid 10.4.2. Lyophilized 10.5. Market Analysis – By End User 10.5.1.Hospitals 10.5.2. Clinics 10.5.3.Homecare 10.6. Market Analysis – By Country/Sub-Region 10.6.1.GCC Countries 10.6.2. South Africa 10.6.3. Rest of Middle East & Africa 11. CompetitiveAnalysis 11.1. Key Industry Developments 11.2. Global Market Share Analysis (2018) 11.3. Competition Dashboard 11.4. Comparative Analysis – Major Players 11.5. Company Profiles (Overview, Products& services, SWOT analysis, Recent developments, strategies, financials(based on availability)) 11.5.1. CSL Behring 11.5.2.Grifols, S.A. 11.5.3. Shire (Takeda Pharmaceutical Company Limited) 11.5.4. Kedrion S.p.A 11.5.5.Octapharma 11.5.6. Bio Products Laboratory Ltd. 11.5.7. Biotest AG 11.5.8. China Biologic Products Holdings, Inc. 11.5.9. LFB SA 11.5.10. ShanghaiRAAS Blood Products Co., Ltd

Shire (Takeda Pharmaceutical Company Limited) CSL Behring Grifols, S.A. Kedrion S.p.A Octapharma Bio Products Laboratory Ltd. Biotest AG China Biologic Products Holdings, Inc. LFB SA Shanghai RAAS Blood Products Co., Ltd. Other players